FOLFIRI Plus Cetuximab Versus Folfiri Plus Bevacizumab as First-Line Treatment of KRAS-Wildtype Metastatic Colorectal Cancer: German AIO Study Krk-0306 (FIRE-3)

Authors :: Ludwig Fischer von Weikersthal
Sebastian Stintzing
Martina Stauch
Werner Scheithauer
Ursula Vehling-Kaiser
Tobias Heintges
Andreas Jung
Britta Schäfer
G. Seipelt
Christoph Kahl
Christian A. Lerchenmuller
Jörg Hielscher
Thomas Decker
Michael Scholz
Frank Kullmann
Volker Heinemann
Sebastian Müller
Dominik Paul Modest
Alexander Kiani
Salah-Eddin Al Batran
Source :: Annals of Oncology. 24:iv22
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: Oncology
medicine.medical_specialty
Bevacizumab
Cetuximab
Colorectal cancer
business.industry
Hematology
medicine.disease
medicine.disease_cause
Fire - disasters
First line treatment
Internal medicine
medicine
FOLFIRI
KRAS
business
medicine.drug

Tools